WAYLIVRA® (volanesorsen) has received conditional marketing authorisation from the European Commission (EC) as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

Read the Press Release

Press release on the approval of WAYLIVRA in the European Union.

Stay up to date on the latest WAYLIVRA news and information.

Learn more about Akcea Therapeutics

Focused on helping patients living with serious and rare diseases.

This medicinal product is subject to additional monitoring. Adverse events should be reported. Summary of Product Characteristics (SmPC) can be found at the following link: https://www.ema.europa.eu/en/medicines/human/EPAR/waylivra#product-information-section